Delivering the next generation of cancer immunotherapies with RNA.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37059063.
- Also identified by DOI 10.1016/j.cell.2023.02.031.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Decades of oncologic clinical use have demonstrated that cancer immunotherapy provides unprecedented therapeutic benefits. Tragically, only a minority of patients respond to existing immunotherapies. RNA lipid nanoparticles have recently emerged as modular tools for immune stimulation. Here, we discuss advancements in RNA-based cancer immunotherapies and opportunities for improvement.
Medical subject headings
- Immunotherapy
- Neoplasms
- RNA